Home > Insider Trading > Filing (0001209191-17-015520)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1513818	Versartis Inc.	VSAR	Pharmaceutical Preparations (2834)	264106690

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1528826	T Joshua Brumm	C/O Versartis, Inc. 4200 Bohannon Drive, Suite 250 Menlo Park CA 94025	Coo And Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-02-24	30,000	$2.53	135,779	No	4	M	Direct
Common Stock	Disposition	2017-02-24	18,339	$20.42	117,440	No	4	S	Direct
Common Stock	Disposition	2017-02-24	6,008	$21.46	111,432	No	4	S	Direct
Common Stock	Disposition	2017-02-24	5,653	$22.05	105,779	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2017-02-24	30,000	$0.00	30,000	$2.53

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
122,108		2023-12-04	No	4	M	Direct

Footnotes

Shares sold pursuant to a 10b5-1 trading plan.
The shares were sold at prices ranging from $19.90 to $20.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each price.
The shares were sold at prices ranging from $20.90 to $21.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each price.
The shares were sold at prices ranging from $21.90 to $22.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each price.
Twenty-Five percent of the shares subject to the option became exercisable one year from 11/12/2013; the remainder become exercisable in equal monthly installments over the following three years.